Clinical trial · Observational
Clinical Implications of Azole-Resistant Aspergillosis in Hematological Malignancy
CLARITY - Clinical Implications of Azole-Resistant Aspergillosis in Hematological Malignancy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In order to determine the efficacy of antifungal therapy in patients with documented azole-resistant invasive Aspergillosis (IA), anonymized clinical information of patients with a hematological malignancy with a culture-positive invasive fungal infection caused by Aspergillus fumigatus are collected in an online registry. Respective fungal isolates are analysed for azole susceptibility and resistance mechanisms. Patients diagnosed with an IA in 2016 and later are included in the study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Invasive Aspergillosis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Registry | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Invasive Aspergillosis
- interventionNames
- Other: Registry
Primary outcomes (1)
- measure
- Treatment response to antifungal therapy in patients with an invasive Aspergillosis caused by an azole resistant pathogen.
- timeFrame
- Change from diagnosis at day 14, 28, 42 and 84 and throughout study completion
- description
- Analysis of efficacy of antifungal therapy of azole-resistant and azole-susceptible invasive Aspergillosis. Patient receive either complete response, partial response, stable disease, progression of the disease. Treatment response will be assessed by treating physicians. Response will be compared between the two groups.
Secondary outcomes (1)
- measure
- Overall survival
- timeFrame
- 4 years
- description
- Final outcome will be compared between the two groups in consideration of the type and state of underlying diseases and risk factors.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Adult and pediatric patients diagnosed with an IA in 2016 and later * Patients with a hematological malignancy * Evidence of invasive Aspergillosis * Aspergillus fumigatus culture from clinical material of the patient Exclusion Criteria: * Colonization only, without proof of invasive infection * Non-availability of the azole resistant isolate
References
Publications (0)
Data not yet available